## Pharmacokinetic Differences: Azithromycin vs Erythromycin **Key Point:** Azithromycin has a significantly longer half-life (40–68 hours) compared to erythromycin (1.5–2 hours), allowing for shorter dosing intervals and better intracellular penetration. ### Structural and Pharmacokinetic Comparison | Property | Erythromycin | Azithromycin | |---|---|---| | Half-life | 1.5–2 hours | 40–68 hours | | Dosing interval | Every 6 hours | Once daily (5 days) or 3 times weekly | | Intracellular accumulation | Moderate | Excellent (100–200× serum levels) | | Protein binding | 70–75% | 50% | | Oral bioavailability | 30–40% (variable) | 37–52% | | Hepatic metabolism | CYP3A4 (major) | Minor hepatic metabolism | | Tissue penetration | Moderate | Superior | **High-Yield:** Azithromycin's long half-life and excellent intracellular accumulation make it ideal for: - Atypical infections (Mycoplasma, Chlamydia, Legionella) - Intracellular pathogens - Respiratory tract infections - Compliance-friendly dosing (shorter course) ### Clinical Advantages of Azithromycin 1. **Longer dosing interval** — improves patient compliance 2. **Superior lung penetration** — alveolar macrophage accumulation 3. **Intracellular accumulation** — effective against intracellular organisms 4. **Lower GI side effects** — better tolerability than erythromycin **Warning:** Despite lower hepatic metabolism, azithromycin still carries risk of QT prolongation and drug interactions via CYP3A4 inhibition (though less than erythromycin). **Clinical Pearl:** Azithromycin's 3-day course (500 mg day 1, then 250 mg daily × 4 days) or single-dose formulations (1.2 g for gonorrhea) are based on its prolonged tissue retention and intracellular accumulation.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.